Sensorion Announces a €15 Million Financing, Extending Cash Runway Until the End of 2025

April 8, 2024

Nawal Ouzren, Sensorion’s Chief Executive Officer, said: “We are thrilled to announce another successful capital raise, securing an additional EUR 15 million to accommodate interest expressed by certain existing investors. This builds on the earlier EUR 50 million financing announced in February 2024, adding up to a total of EUR 100 million raised in less than 9 months. With this new financing, we are well-positioned to accelerate our gene therapy programs, including the progression of SENS-501 through its Phase 1/2 clinical study, Audiogene, and the advancement of our second program, GJB2-GT, towards Clinical Trial Applications submission in H1 2025. The capital increase enables the Company to finance its activities until the end of 2025. We remain deeply thankful for the ongoing support of our shareholders and partners as we strive to make a meaningful difference in the lives of those affected by hearing loss disorders.”

Kryptos Biotechnologies Secures $10 Mil in Series A Funding | Funds to Be Used for Clinical Studies and FDA Approval of their Molecular Diagnostics System

April 4, 2024

Strategic Investor, Osang Healthcare will partner with Kryptos Biotechnologies for the manufacturing and distribution of the product along with financing.

Mother Nurture™ Custom Flexible Orthotics Top the List of Baby Shower Registries: By Jamie Greenawalt, President, Foot Levelers

April 3, 2023

Custom, flexible orthotics rely upon natural pain relief, allowing women to forego pharmaceutical intervention – an important concern since the physiology of pregnancy affects the pharmacokinetics of medications used, and certain medications can reach the fetus and cause harm.

Tackling the Opioid Epidemic with Wearable Technology: By Brad Holden, Co-Founder and CEO of Resilient Lifescience

March 29, 2023

Holden writes, “Resilient Lifescience co-founder Charlie Proctor and I became alarmed by the 22% surge in synthetic opioid deaths during the COVID-19 pandemic and set out to leverage our experience in remote patient monitoring and computer science to develop a solution — a wearable medical device designed to detect and reverse opioid overdoses. Read on to learn how Resilient Lifescience is making a difference!

Driving Innovation and Decreasing Length of Stay with a Referral Management Platform: By Russ Graney

March 28, 2023

Length of stay is both a direct and indirect factor in efficient and effective hospital operations. However, it may be an even more substantial clinical metric today than hospital administrators, management, and executives realize. The impact can be considerable when ignored or de-prioritized. Read on.